ABOUT US
Through continuous R&D with the aim of enhancing the health and lives of people,
we will devote ourselves to helping patients live a healthy life
we will devote ourselves to helping patients live a healthy life
-
About REYONWe continue to innovate and pursue the challenge to become a global bio & chemical pharmaceutical company.
-
R&DWe are advancing to the global market with our R&D model which building a unique platform founded on production technology and state of the art facility.
-
IRA stable and transparent financial structure, the foundation for sustainable growth.
BUSINESS INNOVATIONS
We are creating a future of innovation based on our R&D capabilities and production platform.
REYON NEWS
We will always dream together with our customers and deliver a message of hope and happiness.
-
Samsung Medical Center & REYON Pharmaceutical Signed MOU on Joint R&D for Mass Production of Cellular and Gene Therapy AgentsSamsung Medical Center (SMC; President Park Seung-woo) announced on May 18 that it had signed an MOU on joint RD with REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) on May 11for mass production of cellular and gene therapy products based on Good Manufacturing Practices (GMP). Representatives of the SMC and REYON Pharmaceutical taking a picture at the MOU ceremony held at the Irwon Station campus of the SMC on May 11 The MOU ceremony was held at the Irwon Station campus of the SM...2022.05.18
-
REYON Pharmaceutical Registered Patent for Antifungal Agent in EuropeREYON Pharmaceutical secured a base to advance into the European market by patenting the new drug candidate, RY-108 (iN-EYD), licensed from iNtRON Biotechnology last year, for antifungal use in Europe. REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) announced on May 11 that the European Patent Office (EPO) had approved the patent application for pharmaceutical composition for the treatment of fungal infections caused by Cryptococcus and Candida fungi containing FK506 derivatives ...2022.05.12
-
REYON Pharmaceutical Signed First Agreement for Contract Manufacturing of pDNAREYON Pharmaceutical will start full-fledged production of plasmid DNA (pDNA) at the Chungju bio plant. REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) announced on April 20 that it had signed a pDNA supply contract with INNOPEUTICS (CEO Kim Tae-gyun). REYON Pharmaceutical will produce the pDNA drug substance (DS) and drug product (DP) at the Chungju bio plant and supply it to INNOPEUTICS. The exact value of the contract was not disclosed as agreed between the two companies. REYO...2022.04.20
-
REYON Pharmaceutical Held Completion Ceremony for Chungju Plants and Declares Its Vision as Global Bio & Chemical CompanyREYON Pharmaceutical officially unveiled the Chungju plants built with the aim of serving as global bio chemical drug production platforms and declared its commitment to becoming a global company. REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) held a completion ceremony on April 14 at the Chungju bio and chemical plants (Chungju plants) located in Daesowon-myeon, Chungju-si, Chungcheongbuk-do Province. [Celebrating the completion of construction of the Chungju plants on November...2022.04.14